LOS ANGELES, Dec. 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX) (the “Company”), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, announced today it intends to offer and sell registered shares of its common stock in an underwritten public offering. The Company expects to use the net proceeds of the offering for working capital and general corporate purposes.
Help employers find you! Check out all the jobs and post your resume.
